Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
نویسندگان
چکیده
Introduction: Diabetic macular edema (DME) poses a significant management dilemma for visual impairment. We present a challenging case with terrible centre-involved maculopathy, unsuitable for ranibizumab and heading toward steroid implant relatively soon. To date, no similar reports have been published. Case Presentation: A 54-year-old man presented with poor visual acuity (VA) [right count fingers, left 20/100], bilateral proliferative diabetic retinopathy (PDR) and DME. He was hypertensive, anaemic, had poor renal function and diabetic control. Optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) confirmed mixed maculopathy, worse in right. Management and Outcome: Diabetic parameters were examined and optimized. In the 20 months following urgent laser treatment, he was followed up every three months with serial VA, stereoscopic biomicroscopy and OCT. Despite further laser therapy, his DME persisted, and VA remained poor. A recent stroke precluded ranibizumab use. A flucinolone implant was considered to save his vision. Discussion: Flucinolone implant has recently been approved in Scotland for pseudophakic chronic DME cases unresponsive to other options; effects last 3 years, with promising visual recovery. We plan to perform cataract surgery at the time of flucinolone implantation and monitor intraocular pressure (IOP) and other potential side effects post-operatively. In the manuscript, we provide an integrated treatment approach to help physicians treating chronic DME. Conclusion: Flucinolone has a place as an implantable drug delivery device that offers benefits in chronic DME therapy, adding to a new range of treatment options to suit specific lines and to recover vision in patients previously unresponsive to treatment.
منابع مشابه
Improvement of Diabetic Macular Edema in the Fellow Eye After Monocular Intravitreal Bevacizumab Injection
Introduction: Because of bilateral involvement in many cases with diabetic macular edema, Intravitreal bevacizumab injection perform in both eyes. There are some reports of therapeutic effects in the fellow eye after monocular injection of anti-vascular endothelial growth factors. In this study we describe a case of bilateral improvement of diabetic macular edema following unil...
متن کاملDiabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema
BACKGROUND Kidney failure provoked by glomerulosclerosis leads to fluid filtration deficits and other disorders of kidney function. Refractory diabetic macular edema (DME) can be another warning sign of glomerulosclerosis in diabetic patients. CASE A 40-year-old Saudi male presented with macular edema that was refractory to all possible medical and surgical ophthalmic interventions in both ey...
متن کاملRanibizumab for Diabetic Macular Edema Refractory to Multiple Prior Treatments.
PURPOSE Diabetic macular edema can be refractory to multiple treatment modalities. Although there have been anecdotal reports of ranibizumab showing efficacy when other modalities provided limited benefit, little has been published on treatment for refractory diabetic macular edema. This study sought to investigate this observation further. METHODS Retrospective chart review. RESULTS Thirty...
متن کاملDetermination of serum lipid profile in patients with diabetic macular edema that referred to Shahid Beheshti and Ayatollah Rouhani Hospitals, Babol during 2011-2012
Background: Diabetes is a common metabolic disorder leading to the development of many complications, among which diabetic retinopathy and macular edema are the most significant. These complications can contribute to blindness if not diagnosed or treated properly, and several studies have been conducted to evaluate the methods for the prevention or slowing down their progression. Ther...
متن کامل